Eli Lilly

Eli Lilly & Company is an American pharmaceutical company based in Indianapolis, Indiana.


Bush Family

Former U.S. President George H.W. Bush was a member of the board of directors.1)


Eli Lilly has an exclusive worldwide licensing agreement with Centrexion Therapeutics for CNTX-0290, a novel, small molecule somatostatin receptor type 4 (SSTR4) agonist. At the time of the deal, it was in clinical trials as a potential non-opioid treatment for chronic pain conditions.2)


Eli Lilly has Emergency Use Authorization from the U.S. Food and Drug Administration for three experimental COVID-19 drugs: Bamlanivimab, Etesevimab and Olumiant (in combination with remdesivir).3) 4)

Eli Lilly partnered with Amgen to manufacture their COVID-19 antibody therapy products.5) A similar partnership exists with AbCellera, which recently led to the release of a second product called Bebtelovimab, alleged to work against Omicron.6)

Eli Lilly is also part of the COVID-19 Therapeutics Accelerator funded by the Bill & Melinda Gates Foundation, Wellcome Trust, and Mastercard to “accelerate treatments, vaccines, and diagnostics.”7)

Levine, B. (2004, May). Eli Lilly, Zyprexa, & the Bush Family. Z Magazine. https://archive.ph/dIGJx
Taylor, M., Hern, K., Normart, J., & Dugan, C. (2019, May 28). Lilly Announces Licensing Agreement for Non-Opioid Pain Asset from Centrexion Therapeutics. Eli Lilly. https://investor.lilly.com/news-releases/news-release-details/lilly-announces-licensing-agreement-non-opioid-pain-asset
O’Shaughnessy, J. A., PhD. (2021, December 3). RE: Emergency Use Authorization 094. Eli Lilly. Retrieved December 6, 2021, from http://pi.lilly.com/eua/bam-and-ete-eua-fda-authorization-letter.pdf
Hinton, D. M. (2021, July 28). Baricitinib EUA FDA Authorization Letter. Eli Lilly. Retrieved December 6, 2021, from http://pi.lilly.com/eua/baricitinib-eua-fda-authorization-letter.pdf
Taylor, M., & Rowland, T. (2020, September 17). Lilly and Amgen Announce Manufacturing Collaboration for COVID-19 Antibody Therapies. Amgen. https://archive.ph/pXXV5
Yingling, J. (2022, February 10). Lilly to Supply up to 600,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatments. AbCellera. https://archive.ph/odx6M
Staines, R. (2020, March 26). Pharma giants including Novartis collaborate on COVID-19 therapies. Pharmaphorum; Pharmaphorum Media Limited. https://archive.ph/8TAzM